New Research from the CWMH: No Increase in Major Malformations in Children with Prenatal Exposure to Olanzapine
No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.
No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.
Despite the increasing use of the newer atypical or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including psychotic disorders, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little [...]
The use of the newer “atypical” or second-generation antipsychotic (SGA) agents continues to increase. These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders. [...]
We are excited to announce the enrollment of our 1000th participant in the National Pregnancy Registry for Atypical Antipsychotics! Formed in 2008, the Registry was established at MGH to prospectively evaluate the rates of [...]
We would like to thank you for your continuing support of the National Pregnancy Registry for Atypical Antipsychotics (NPRAA) at the Center for Women’s Mental Health at Massachusetts General Hospital. We are grateful for all the referrals made to the Registry as our numbers continue to grow every day. Given the Registry’s successful enrollment, we are pleased to announce our plan to release preliminary data at an upcoming conference in June, the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.